December 23, 2019 09:53 AM EST

J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech

Amber Tong

J&J is scooping up one of Bristol-Myers-Squibb’s biotech partners specialized in bladder biology, with a particularly keen interest in a technology that releases cancer drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

J&J rounds out the year with twin buy­outs, gain­ing con­trol of de­liv­ery and sur­gi­cal ro­bot­ics tech

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech